Aberrant histone deacetylase 1 expression upregulates vimentin expression via an NF‑κB‑dependent pathway in hepatocellular carcinoma

Zhou,Huancheng; Xu,Jiwei; Zhang,Caiyun; Wen,Yuanzhang

doi:10.3892/ol.2019.10309

Aberrant histone deacetylase 1 expression upregulates vimentin expression via an NF‑κB‑dependent pathway in hepatocellular carcinoma

Authors:
- Huancheng Zhou
- Jiwei Xu
- Caiyun Zhang
- Yuanzhang Wen
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Meizhou People's Hospital, Meizhou, Guangdong 514031, P.R. China
Published online on: May 3, 2019 https://doi.org/10.3892/ol.2019.10309
Pages: 339-347
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrantly elevated expression levels of histone deacetylase 1 (HDAC1) and vimentin are closely associated with disease progression in hepatocellular carcinoma (HCC). It was previously demonstrated that knocking down expression of HDAC1 resulted in a concurrent decrease in the expression levels of vimentin. However, a causal link between these two proteins has not yet been demonstrated, to the best of our knowledge. In the present study, the association between HDAC1 and vimentin was investigated using an HDAC1 overexpression platform. HDAC1 and vimentin were significantly increased in HCC cells, and HDAC1 overexpression enhanced vimentin mRNA and protein expression levels in an HDAC1 dose‑dependent manner. Subsequently, truncation and mutation of a vimentin promoter demonstrated that HDAC1‑induced vimentin expression was dependent on a nuclear factor κ‑light‑chain‑enhancer of activated B cells (NF‑κB) binding site in the vimentin promoter sequence. Furthermore, HDAC1 induced vimentin expression by promoting NF‑κB translocation between the cytoplasm and the nucleus, as opposed to modulating the total expression level of vimentin directly. The data in the present study demonstrated that HDAC1 is overexpressed in HCC and that HDAC1 may upregulate vimentin expression through the NF‑κB signaling pathway, thus demonstrating a causal link between HDAC1 and vimentin in HCC, and may provide valuable information in understanding the pathogenesis of HCC.

View Figures

View References

1	World-Health-Organization, . Cancer (fact sheet) 2018. https://www.who.int/en/news-room/fact-sheets/detail/cancerSeptember 12–2018
2	Ito Y, Takeda T, Higashiyama S, Sakon M, Wakasa KI, Tsujimoto M, Monden M and Matsuura N: Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: An immunohistochemical study. Oncol Rep. 8:903–907. 2001.PubMed/NCBI
3	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
4	Bosch FX, Ribes J, Diaz M and Cleries R: Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 127:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
5	Waly Raphael S, Yangde Z and YuXiang C: Hepatocellular carcinoma: Focus on different aspects of management. ISRN Oncol. 2012:4216732012.PubMed/NCBI
6	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
7	Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M and Falck-Ytter Y: Eradication of Hepatitis C virus infection and the development of hepatocellular carcinomaa: A meta-analysis of observational studies. Ann Intern Med. 158:329–337. 2013. View Article : Google Scholar : PubMed/NCBI
8	Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, et al: Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol. 12:885–893. 2014. View Article : Google Scholar : PubMed/NCBI
9	Kirstein MM and Vogel A: The pathogenesis of hepatocellular carcinoma. Dig Dis. 32:545–553. 2014. View Article : Google Scholar : PubMed/NCBI
10	Kaliman P, Álvarez-López MJ, Cosín-Tomás M, Rosenkranz MA, Lutz A and Davidson RJ: Rapid changes in histone deacetylases and inflammatory gene expression in expert meditators. Psychoneuroendocrinology. 40:96–107. 2014. View Article : Google Scholar : PubMed/NCBI
11	Shankar S and Srivastava RK: Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol. 615:261–298. 2008. View Article : Google Scholar : PubMed/NCBI
12	Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M and Maehara Y: Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 72:69–74. 2007. View Article : Google Scholar : PubMed/NCBI
13	Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE and Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 59:177–189. 2004. View Article : Google Scholar : PubMed/NCBI
14	Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ and Kim DY: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 92:1300–1304. 2001. View Article : Google Scholar : PubMed/NCBI
15	Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D and Ocker M: Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 459:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
16	Seo J, Min SK, Park HR, Kim DH, Kwon MJ, Kim LS and Ju YS: Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in invasive ductal carcinomas of the breast. J Breast Cancer. 17:323–331. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ropero S and Esteller M: The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25. 2007. View Article : Google Scholar : PubMed/NCBI
18	Peng L and Seto E: Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol. 206:39–56. 2011. View Article : Google Scholar : PubMed/NCBI
19	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nature Rev Cancer. 2:442–454. 2002. View Article : Google Scholar
20	Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, Huang M, Wang Y, Wu MC, Huang JF, et al: Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene. 23:298–302. 2004. View Article : Google Scholar : PubMed/NCBI
21	Mitra A, Satelli A, Xia X, Cutrera J, Mishra L and Li S: Cell-surface Vimentin: A mislocalized protein for isolating csVimentin(+) CD133(−) novel stem-like hepatocellular carcinoma cells expressing EMT markers. Int J Cancer. 137:491–496. 2015. View Article : Google Scholar : PubMed/NCBI
22	Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ and Luk JM: Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm). J Proteome Res. 9:1923–1930. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zhou H, Wang J, Peng G, Song Y and Zhang C: A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system. Int J Clin Exp Med. 8:17721–17729. 2015.PubMed/NCBI
24	Wu Y, Zhang X, Salmon M, Lin X and Zehner ZE: TGFbeta1 regulation of vimentin gene expression during differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members. Biochim Biophys Acta. 1773:427–439. 2007. View Article : Google Scholar : PubMed/NCBI
25	livak kj and schmittgen td: analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Huang W, Hu K, Luo S, Zhang M, Li C, Jin W, Liu Y, Griffin GE, Shattock RJ and Hu Q: Herpes simplex virus type 2 infection of human epithelial cells induces CXCL9 expression and CD4+ T cell migration via activation of p38-CCAAT/enhancer-binding protein-β pathway. J Immunol. 188:6247–6257. 2012. View Article : Google Scholar : PubMed/NCBI
27	Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V and Gottlieb AB: Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 124:1275–1283. 2005. View Article : Google Scholar : PubMed/NCBI
28	Ler SY, Leung CH, Khin LW, Lu GD, Salto-Tellez M, Hartman M, Iau PT, Yap CT and Hooi SC: HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncol Rep. 34:2238–2250. 2015. View Article : Google Scholar : PubMed/NCBI
29	Sun TY, Xie HJ, Li Z, Kong LF and Ding YZ: Analysis of miRNAs related to abnormal HDAC1 expression in hepatocellular carcinoma. Int J Clin Exp Med. 9:2016.
30	Yoo YG, Na TY, Seo HW, Seong JK, Park CK, Shin YK and Lee MO: Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene. 27:3405–3413. 2008. View Article : Google Scholar : PubMed/NCBI
31	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
32	Salvi A, Bongarzone I, Ferrari L, Abeni E, Arici B, De Bortoli M, Scuri S, Bonini D, Grossi I, Benetti A, et al: Molecular characterization of LASP-1 expression reveals vimentin as its new partner in human hepatocellular carcinoma cells. Int J Oncol. 46:1901–1912. 2015. View Article : Google Scholar : PubMed/NCBI
33	Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, Sheng Y, Zheng Y, Yu J, Xie L, et al: Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget. 7:12997–13012. 2016. View Article : Google Scholar : PubMed/NCBI
34	Harms KL and Chen X: Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67:3145–3152. 2007. View Article : Google Scholar : PubMed/NCBI
35	Lei WW, Zhang KH, Pan XC, Wang DM, Hu Y, Yang YN and Song JG: Histone deacetylase 1 and 2 differentially regulate apoptosis by opposing effects on extracellular signal-regulated kinase 1/2. Cell Death Dis. 1:e442010. View Article : Google Scholar : PubMed/NCBI
36	De Ruijter AJ, Van Gennip AH, Caron HN, Stephan K and Van Kuilenburg AB: Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J. 370:737–749. 2003. View Article : Google Scholar : PubMed/NCBI
37	Yadav A, Kumar B, Datta J, Teknos TN and Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
38	Du R, Sun W, Xia L, Zhao A, Yu Y, Zhao L, Wang H, Huang C and Sun S: Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One. 7:e307712012. View Article : Google Scholar : PubMed/NCBI
39	Sarria AJ, Nordeen SK and Evans RM: Regulated expression of vimentin cDNA in cells in the presence and absence of a preexisting vimentin filament network. J Cell Biol. 111:553–565. 1990. View Article : Google Scholar : PubMed/NCBI